...
首页> 外文期刊>Medical oncology >Overexpression of Sig1R is closely associated with tumor progression and poor outcome in patients with hilar cholangiocarcinoma
【24h】

Overexpression of Sig1R is closely associated with tumor progression and poor outcome in patients with hilar cholangiocarcinoma

机译:Sig1R的过表达与肝门部胆管癌患者的肿瘤进展和不良预后密切相关

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Nonopioid Sigma1 receptor (Sig1R), which regulates various metabolism functions, has been implicated in cancers; yet, its role in hilar cholangiocarcinoma remains unclear. In the present study, we examined Sig1R expression in hilar cholangiocarcinoma (HC) tissues and explored its possible clinical values. Tissue microarray blocks containing 92 HC tissues and matched non-cancerous bile duct tissues were examined immunohistochemically for expression of Sig1R protein. Overexpression of Sig1R was found in 43 (46.7 %) of the 92 primary tumor tissues. Overexpression of Sig1R was significantly associated with poor/undifferentiation (P = 0.011), tumor invasion (P = 0.001), lymph node metastasis (P = 0.047), and advanced disease stage (P = 0.024) of HC patients. Kaplan-Meier analysis showed that patients overexpressing Sig1R had an earlier recurrence and worse overall survival than those not overexpressing Sig1R. Cox regression analysis revealed that Sig1R was an independent factor to predict HC recurrence and prognosis of HC patients. Our results suggest that Sig1R is frequently activated in human HC tissue and overexpression of Sig1R might serve as a predictor for tumor recurrence and a prognostic biomarker for HC patients.
机译:调节多种新陈代谢功能的Nonopioid Sigma1受体(Sig1R)与癌症有关。然而,其在肝门胆管癌中的作用仍不清楚。在本研究中,我们检查了肝门胆管癌(HC)组织中的Sig1R表达,并探讨了其可能的临床价值。免疫组织化学检查包含92个HC组织和匹配的非癌性胆管组织的组织微阵列模块的Sig1R蛋白表达。在92例原发性肿瘤组织中有43例(46.7%)发现Sig1R过表达。 Sig1R的过表达与HC患者的差/未分化(P = 0.011),肿瘤浸润(P = 0.001),淋巴结转移(P = 0.047)和疾病晚期(P = 0.024)显着相关。 Kaplan-Meier分析表明,与未过表达Sig1R的患者相比,过表达Sig1R的患者具有较早的复发率和较差的总体生存率。 Cox回归分析显示Sig1R是预测HC复发和HC患者预后的独立因素。我们的结果表明,Sig1R在人HC组织中经常被激活,Sig1R的过度表达可能成为HC患者肿瘤复发的预测因子和预后生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号